GO:0140646 negative regulation of pre-B cell receptor expression: Regulation, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0140646 describes any process that stops, prevents, or reduces the expression of the pre-B cell receptor (pre-BCR) on the surface of pre-B cells.
• The pre-BCR checkpoint is a critical developmental stage where B cells test successful immunoglobulin heavy chain rearrangement; negative regulation prevents autoimmunity and uncontrolled clonal expansion.
• Key negative regulators include BACH2, KLF2, IKAROS, Fc gamma RIIB, and the CCR4-NOT complex, which act at transcriptional, post-transcriptional, and signaling levels.
• Dysregulation of this process is linked to B-cell acute lymphoblastic leukemia (B-ALL), particularly Philadelphia chromosome-positive ALL, and to autoimmune conditions.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect the causal roles of these regulators in pre-BCR expression.
• Understanding GO:0140646 provides insights into B-cell development, leukemia, and potential therapeutic targets for B-cell malignancies.
Description
The pre-B cell receptor (pre-BCR) is a transient surface complex expressed on developing B cells that serves as a critical checkpoint for immunoglobulin heavy chain (IgH) assembly and B cell selection. The process of pre-BCR expression is tightly regulated to ensure proper B cell development and prevent autoimmunity. GO:0140646, negative regulation of pre-B cell receptor expression, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of pre-BCR expression on the surface of pre-B cells. This regulation is essential for controlling clonal expansion, allelic exclusion, and the transition from pre-B to immature B cells. Researchers study this term to understand how developing B cells integrate signals from the pre-BCR to make life-or-death decisions. Negative regulators such as BACH2, KLF2, and IKAROS modulate pre-BCR signaling and expression, and their dysfunction can lead to hematological malignancies. For example, loss of IKAROS function in Philadelphia chromosome-positive acute lymphoblastic leukemia impairs pre-BCR-mediated cell cycle arrest, contributing to leukemogenesis. Similarly, the CCR4-NOT complex regulates mRNA decay of pre-BCR components, adding another layer of post-transcriptional control. This article synthesizes authoritative QuickGO data and verified PubMed literature to provide a comprehensive overview of GO:0140646, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and experimental approaches including CRISPR-based models. By understanding this process, researchers can better target pathways for therapeutic intervention in B-cell disorders.
negative regulation of pre-B cell receptor expression At A Glance
| GO ID | GO:0140646 |
|---|---|
| GO term | negative regulation of pre-B cell receptor expression |
| Ontology | biological_process |
| Synonym | None |
| Major function | Suppression of pre-BCR surface expression to control B cell development, clonal expansion, and selection |
| Related processes | B cell differentiation, pre-BCR signaling, allelic exclusion, apoptosis, cell cycle arrest |
| Key regulators | BACH2, KLF2, IKAROS, Fc gamma RIIB, CCR4-NOT complex |
| Disease relevance | B-cell acute lymphoblastic leukemia, autoimmunity |
| Experimental approaches | CRISPR knockout, point mutation, knock-in, overexpression, RNA-seq, flow cytometry |
What Is GO:0140646?
GO:0140646, negative regulation of pre-B cell receptor expression, is a biological process defined as any process that stops, prevents, or reduces the frequency, rate, or extent of the process leading up to expression of the pre-B cell receptor on the surface of pre-B cells. In simpler terms, it includes all molecular and cellular events that suppress the production or surface presentation of the pre-BCR, a key developmental checkpoint receptor in B lymphocytes.
Why Is negative regulation of pre-B cell receptor expression Important in Cell Biology?
Negative regulation of pre-B cell receptor expression is crucial for proper B cell development and immune homeostasis. The pre-BCR checkpoint ensures that only B cells with functional immunoglobulin heavy chains survive and proliferate, while autoreactive or non-functional clones are eliminated. Negative regulators fine-tune this process to prevent excessive clonal expansion and autoimmunity. Dysregulation of these regulators is directly implicated in B-cell malignancies, particularly Philadelphia chromosome-positive acute lymphoblastic leukemia, where impaired pre-BCR-mediated cell cycle arrest contributes to leukemogenesis. Thus, understanding GO:0140646 offers insights into basic immunology and provides potential therapeutic targets for B-cell disorders.
• Controls the pre-BCR checkpoint, ensuring only B cells with successful IgH rearrangement survive.
• Prevents uncontrolled clonal expansion of pre-B cells.
• Regulates allelic exclusion to maintain monospecific B cell receptors.
• Modulates apoptosis and cell cycle arrest in developing B cells.
• Dysregulation leads to B-cell acute lymphoblastic leukemia, especially Ph+ ALL.
• Involved in autoimmune diseases through breakdown of self-tolerance.
• Provides targets for therapeutic intervention in B-cell malignancies.
• Integrates metabolic and signaling cues via transcription factors like BACH2 and IKAROS.
• Post-transcriptional control by CCR4-NOT complex adds another regulatory layer.
• Essential for understanding normal and malignant B cell development.
What Happens During negative regulation of pre-B cell receptor expression?
Transcriptional repression of pre-BCR components
In simple terms: Certain transcription factors act as brakes to reduce the production of pre-BCR parts.
Transcription factors such as BACH2 and KLF2 negatively regulate the expression of pre-BCR components. BACH2 balances with BCL6 to control selection at the pre-B cell receptor checkpoint. KLF2 acts as a negative regulator of pre-B cell clonal expansion and B cell activation, thereby influencing pre-BCR expression. These factors bind to regulatory regions of genes encoding pre-BCR subunits (e.g., Igll1, Vpreb1) and repress their transcription, reducing surface pre-BCR levels.
Post-transcriptional mRNA decay
In simple terms: After mRNA is made, it can be destroyed before it makes protein, lowering pre-BCR levels.
The CCR4-NOT complex catalyzes mRNA deadenylation and decay of transcripts encoding pre-BCR components, thereby negatively regulating pre-BCR expression. This post-transcriptional mechanism ensures rapid downregulation of pre-BCR upon developmental cues or signaling feedback.
Signaling inhibition by Fc gamma RIIB
In simple terms: An inhibitory receptor can block signals that would otherwise promote pre-BCR expression.
Fc gamma RIIB negatively regulates pre-BCR signaling for apoptosis, thereby indirectly affecting pre-BCR expression levels. By recruiting phosphatases, Fc gamma RIIB dampens BCR-like signaling, which can lead to reduced pre-BCR surface expression and altered selection outcomes.
IKAROS-mediated cell cycle arrest
In simple terms: IKAROS stops cell division when pre-BCR signals are too strong, preventing excessive expansion.
IKAROS is required for pre-BCR-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia. Loss of IKAROS function abrogates this negative regulation, leading to uncontrolled proliferation of pre-B cells. Thus, IKAROS acts as a negative regulator of pre-BCR expression and downstream proliferation.
Metabolic gatekeeper control
In simple terms: Metabolism can influence whether pre-BCR expression is turned down.
B-lymphoid transcription factors such as IKAROS and PAX5 act as metabolic gatekeepers, limiting glucose uptake and energy supply to pre-B cells. This metabolic restriction negatively regulates pre-BCR expression and signaling, coupling developmental checkpoints to cellular metabolism.
Key Genes Involved in GO:0140646 negative regulation of pre-B cell receptor expression
The following genes and proteins are key players in the negative regulation of pre-B cell receptor expression, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| BACH2 | Transcription factor that balances with BCL6 to regulate pre-BCR checkpoint selection | Controls B cell selection and prevents autoimmunity |
| KLF2 | Negative regulator of pre-B cell clonal expansion and B cell activation | Limits pre-BCR-driven proliferation |
| IKAROS | Transcription factor required for pre-BCR-mediated cell cycle arrest | Tumor suppressor in Ph+ ALL |
| Fc gamma RIIB | Inhibitory receptor that negatively regulates pre-BCR signaling for apoptosis | Modulates B cell selection and apoptosis |
| CCR4-NOT complex | mRNA decay machinery that degrades pre-BCR transcripts | Post-transcriptional control of pre-BCR expression |
| BCL6 | Transcriptional repressor that opposes BACH2 at the pre-BCR checkpoint | Balances selection outcomes |
| PAX5 | B-lymphoid transcription factor with metabolic gatekeeper function | Limits pre-BCR expression via metabolic control |
| Igll1 (lambda5) | Pre-BCR component; its expression is negatively regulated | Target of transcriptional and post-transcriptional repression |
| Vpreb1 | Pre-BCR component; its expression is negatively regulated | Target of transcriptional and post-transcriptional repression |
| CD79a (Ig alpha) | Pre-BCR signaling subunit; expression modulated | Component of pre-BCR complex |
| CD79b (Ig beta) | Pre-BCR signaling subunit; expression modulated | Component of pre-BCR complex |
| BLNK | Adapter protein in pre-BCR signaling; may be regulated | Downstream of pre-BCR |
| SYK | Kinase in pre-BCR signaling; activity modulated | Downstream of pre-BCR |
| BTK | Kinase in pre-BCR signaling; activity modulated | Downstream of pre-BCR |
| PI3K | Signaling pathway downstream of pre-BCR; negatively regulated | Metabolic control |
| FOXO1 | Transcription factor inhibited by PI3K; affects pre-BCR expression | Metabolic gatekeeper |
| MYC | Oncogene regulated by pre-BCR signaling; negatively regulated | Proliferation control |
How Is negative regulation of pre-B cell receptor expression Regulated?
The negative regulation of pre-B cell receptor expression is itself controlled by multiple feedback loops and signaling pathways. The pre-BCR signals through SYK, BTK, and PI3K, which can activate negative feedback mechanisms. For instance, PI3K activation leads to FOXO1 inhibition, which in turn affects metabolic and transcriptional programs that limit pre-BCR expression. BACH2 and BCL6 form a balance that regulates selection at the pre-BCR checkpoint, with BACH2 promoting negative regulation. Additionally, the CCR4-NOT complex is regulated by developmental cues to degrade pre-BCR mRNAs. IKAROS function is modulated by signaling downstream of the pre-BCR, and its loss abrogates cell cycle arrest. These regulatory layers ensure precise control of pre-BCR expression during B cell development.
negative regulation of pre-B cell receptor expression and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IKAROS | Ph+ acute lymphoblastic leukemia | CRISPR knockout in Ph+ ALL cell lines (e.g., SUP-B15) |
| BACH2 | Autoimmunity, B-ALL | Knockout or overexpression in murine B cell progenitors |
| KLF2 | Autoimmune activation, lymphoma | Conditional knockout mouse models |
| Fc gamma RIIB | Systemic lupus erythematosus | Knockout mice and human B cell lines |
| CCR4-NOT complex | B cell development defects | CRISPR knockout of CNOT subunits in pre-B cell lines |
B-cell acute lymphoblastic leukemia (B-ALL)
Dysregulation of negative regulation of pre-BCR expression is a hallmark of B-ALL, particularly Philadelphia chromosome-positive ALL. Loss of IKAROS function impairs pre-BCR-mediated cell cycle arrest, leading to uncontrolled proliferation of leukemic blasts. Metabolic gatekeeper functions of IKAROS and PAX5 are also compromised in B-ALL, contributing to leukemogenesis. Targeting these pathways may offer therapeutic strategies.
Autoimmune diseases
Defects in negative regulation of pre-BCR expression can lead to escape of autoreactive B cells. BACH2-BCL6 imbalance alters selection at the pre-BCR checkpoint, potentially promoting autoimmunity. KLF2 deficiency leads to increased B cell activation, which may contribute to autoimmune phenotypes.
Immunodeficiency
Impaired pre-BCR expression or signaling can cause agammaglobulinemia. While negative regulation is essential, its dysregulation might also disrupt B cell development, leading to reduced antibody production.
From negative regulation of pre-B cell receptor expression-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate pre-BCR expression? | CRISPR knockout in pre-B cell lines (e.g., NALM6, 697) followed by flow cytometry |
| What is the effect of a point mutation in a regulator? | CRISPR point mutation knock-in in cell lines or primary cells |
| How does a regulator affect pre-BCR signaling? | Knock-in of tagged regulator for proteomics and imaging |
| Can overexpression of a regulator suppress pre-BCR? | Overexpression via lentiviral transduction in pre-B cells |
| What are the downstream targets of a regulator? | RNA-seq and Ribo-seq after CRISPR knockout |
| Does a regulator control clonal expansion? | In vivo mouse models with conditional knockout |
How to Study the negative regulation of pre-B cell receptor expression Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface pre-BCR protein levels | Quantify negative regulation in cell lines and primary cells |
| RNA-seq | mRNA levels of pre-BCR components | Identify transcriptional repression |
| Ribo-seq | Translation efficiency of pre-BCR mRNAs | Detect post-transcriptional control |
| Proteomics | Protein interactions and complexes | Identify regulators like CCR4-NOT |
| CRISPR screen | Genes affecting pre-BCR expression | Discover novel negative regulators |
| Immunoblotting | Protein levels of pre-BCR subunits | Validate knockdown/knockout effects |
| Chromatin immunoprecipitation (ChIP) | Transcription factor binding to pre-BCR gene loci | Map BACH2, KLF2 binding sites |
| Reporter assays | Transcriptional activity of pre-BCR promoters | Test regulatory elements |
Flow cytometry for surface pre-BCR
Flow cytometry using antibodies against pre-BCR components (e.g., lambda5, Vpreb) is the gold standard to measure surface pre-BCR expression. This method allows quantification of negative regulation at the single-cell level and is widely used in B cell development studies.
RNA-seq and Ribo-seq
RNA sequencing measures transcript levels of pre-BCR components, while Ribo-seq measures their translation. These methods can reveal transcriptional and post-transcriptional negative regulation, such as mRNA decay by CCR4-NOT.
Proteomics and immunoprecipitation
Mass spectrometry-based proteomics and co-immunoprecipitation can identify protein complexes involved in negative regulation, such as the CCR4-NOT complex or transcription factor complexes.
CRISPR screens
Genome-wide CRISPR knockout or activation screens can identify novel negative regulators of pre-BCR expression. Cells are sorted based on pre-BCR surface levels, and sgRNAs are sequenced to identify enriched or depleted genes.
How CRISPR Can Be Used to Study GO:0140646 negative regulation of pre-B cell receptor expression
Knockout
CRISPR knockout of candidate negative regulators (e.g., BACH2, KLF2, IKAROS) in pre-B cell lines or primary cells can reveal their role in suppressing pre-BCR expression. For example, IKAROS knockout in Ph+ ALL cells abrogates pre-BCR-mediated cell cycle arrest. Knockout models are essential for loss-of-function studies.
Point Mutation
CRISPR point mutation knock-in can model specific missense or nonsense mutations found in patients. For instance, introducing mutations in IKAROS DNA-binding domain can dissect its role in pre-BCR regulation. This approach provides insights into structure-function relationships.
Knock-in
Knock-in of tagged versions of regulators (e.g., GFP or HA tags) allows for live-cell imaging and proteomic analysis. Tagged CCR4-NOT subunits can be used to study mRNA decay of pre-BCR transcripts. Knock-in of reporter genes under pre-BCR promoters can monitor expression dynamics.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can force high levels of candidate negative regulators. Overexpressing BACH2 or KLF2 in pre-B cells can suppress pre-BCR expression and inhibit proliferation. This approach is useful for gain-of-function studies.
How EDITGENE Supports negative regulation of pre-B cell receptor expression Research
Researchers studying negative regulation of pre-B cell receptor expression-related genes often need to determine whether a candidate gene is causally involved in suppressing pre-BCR surface levels, and to dissect the underlying molecular mechanisms. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from gene knockout to precise point mutations and overexpression models.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of pre-B cell receptor expression research.
Frequently Asked Questions About negative regulation of pre-B cell receptor expression
What is GO:0140646?
GO:0140646 is the Gene Ontology term for negative regulation of pre-B cell receptor expression, describing any process that stops, prevents, or reduces the expression of the pre-BCR on pre-B cells.
What genes are involved in negative regulation of pre-B cell receptor expression?
Key genes include BACH2, KLF2, IKAROS, Fc gamma RIIB, and components of the CCR4-NOT complex.
Why is negative regulation of pre-BCR important?
It controls the pre-BCR checkpoint, preventing autoimmunity and uncontrolled clonal expansion, and its dysregulation is linked to B-ALL.
What diseases are associated with defects in this process?
B-cell acute lymphoblastic leukemia, particularly Philadelphia chromosome-positive ALL, and autoimmune diseases.
How can I study negative regulation of pre-BCR expression?
Use CRISPR knockout, point mutation, knock-in, overexpression models, flow cytometry, RNA-seq, and CRISPR screens.
What is the pre-B cell receptor?
The pre-BCR is a transient surface receptor on developing B cells that tests successful immunoglobulin heavy chain rearrangement.
Which transcription factors repress pre-BCR expression?
BACH2, KLF2, and IKAROS are transcription factors that negatively regulate pre-BCR expression.
How does the CCR4-NOT complex regulate pre-BCR?
It catalyzes mRNA decay of pre-BCR transcripts, reducing protein production.
What is the role of IKAROS in pre-BCR regulation?
IKAROS is required for pre-BCR-mediated cell cycle arrest; its loss leads to uncontrolled proliferation in Ph+ ALL.
Can CRISPR be used to study this process?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression are powerful tools to dissect gene function in pre-BCR regulation.
Conclusion
GO:0140646, negative regulation of pre-B cell receptor expression, is a critical biological process that ensures proper B cell development and immune tolerance. Through transcriptional repression, mRNA decay, and signaling inhibition, key regulators like BACH2, KLF2, IKAROS, and the CCR4-NOT complex fine-tune pre-BCR levels. Dysregulation of this process contributes to B-cell malignancies and autoimmunity, making it a compelling area for research and therapeutic targeting. Advances in CRISPR-based models and high-throughput methods continue to unravel the complexities of this regulatory network.
References
- 1. Chan LN et al.. 2017. Metabolic gatekeeper function of B-lymphoid transcription factors.. Nature 542(7642):479-483 PMID: 28192788
- 2. Muljo SA et al.. 2000. Pre-B and pre-T-cell receptors: conservation of strategies in regulating early lymphocyte development.. Immunol Rev 175:80-93 PMID: 10933593
- 3. Swaminathan S et al.. 2014. BACH2-BCL6 balance regulates selection at the pre-B cell receptor checkpoint.. Trends Immunol 35(3):131-7 PMID: 24332591
- 4. Winkelmann R et al.. 2014. KLF2--a negative regulator of pre-B cell clonal expansion and B cell activation.. PLoS One 9(5):e97953 PMID: 24874925
- 5. Kato I et al.. 2002. The pre-B cell receptor signaling for apoptosis is negatively regulated by Fc gamma RIIB.. J Immunol 168(2):629-34 PMID: 11777955
- 6. Trageser D et al.. 2009. Pre-B cell receptor-mediated cell cycle arrest in Philadelphia chromosome-positive acute lymphoblastic leukemia requires IKAROS function.. J Exp Med 206(8):1739-53 PMID: 19620627
- 8. Akiyama T et al.. 2021. Regulation of Early Lymphocyte Development via mRNA Decay Catalyzed by the CCR4-NOT Complex.. Front Immunol 12:715675 PMID: 34349771
